Association of lipoprotein(a) with long‐term mortality following coronary angiography or percutaneous coronary intervention

• Published in: Clinical cardiology (Mahwah, N.J.) Vol. 40; no. 9; pp. 674 - 678
• Main Authors: Feng, Zhe, Li, Hua‐long, Bei, Wei‐jie, Guo, Xiao‐sheng, Wang, Kun, Yi, Shi‐xin, Luo, De‐mou, Li, Xi‐da, Chen, Shi‐qun, Ran, Peng, Chen, Peng‐yuan, Islam, Sheikh Mohammed Shariful, Chen, Ji‐yan, Liu, Yong, Zhou, Ying‐ling
• Format: Journal Article
• Language: English
• Published: New York Wiley Periodicals, Inc 01.09.2017; John Wiley & Sons, Inc
• Subjects: Aged; Angioplasty; Biomarkers - blood; Chi-Square Distribution; Clinical Investigations; Coronary Angiography; Coronary Angiography - adverse effects; Coronary Angiography - mortality; Coronary Artery Disease - blood; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - mortality; Coronary Artery Disease - therapy; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Lipoprotein(a); Lipoprotein(a) - blood; Male; Medical imaging; Middle Aged; Mortality; Multivariate Analysis; Percutaneous Coronary Intervention; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - mortality; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Coronary Angiography; Lipoprotein(a); Mortality; Percutaneous Coronary Intervention
• DOI: 10.1002/clc.22712
• ISSN: 0160-9289; 1932-8737

Background There is no consistent evidence to suggest the association of plasma lipoprotein(a) (Lp[a]) with long‐term mortality in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). Hypothesis Level of Lp(a) is associated with long‐term mortality following CAG or PCI. Methods We enrolled 1684 patients with plasma Lp(a) data undergoing CAG or PCI between April 2009 and December 2013. The patients were divided into 2 groups: a low‐Lp(a) group (Lp[a] <16.0 mg/dL; n = 842) and a high‐Lp(a) group (Lp[a] ≥16.0 mg/dL; n = 842). Results In‐hospital mortality was not significantly different between the high and low Lp(a) groups (0.8% vs 0.5%, respectively; P = 0.364). During the median follow‐up period of 1.95 years, the high‐Lp(a) group had a higher long‐term mortality than did the low‐Lp(a) group (5.8% vs 2.5%, respectively; P = 0.003). After adjustment of confounders, multivariate Cox regression analysis revealed that a higher Lp(a) level was an independent predictor of long‐term mortality (hazard ratio: 1.96, 95% confidence interval: 1.07‐3.59, P = 0.029). Conclusions Our data suggested that an elevated Lp(a) level was significantly associated with long‐term mortality following CAG or PCI. However, additional larger multicenter studies will be required to investigate the predictive value of Lp(a) levels and evaluate the benefit of controlling Lp(a) levels for patients undergoing CAG or PCI.